{"disease":{"id":"lung-cancer-non-small-cell-cancer-nsclc","name":"lung cancer non small cell cancer nsclc"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03505515","title":"Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":6205,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT07222566","title":"Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":1410,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT06881784","title":"Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":420,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT06747026","title":"Real-World Immuno-Radiotherapy for Advanced NSCLC","phase":"","overall_status":"COMPLETED","enrollment_count":338,"lead_sponsor_name":"Fengming Kong","has_results":false},{"nct_id":"NCT07491211","title":"Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT07510724","title":"Real-World Data on the Treatment of Lung Cancer Patients With the Immune-Checkpoint Inhibitor Tislelizumab","phase":"","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","has_results":false},{"nct_id":"NCT06810609","title":"Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":176,"lead_sponsor_name":"University Hospital, Bonn","has_results":false},{"nct_id":"NCT06705465","title":"Cross-sectorial Rehabilitation of Patients with Lung Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":130,"lead_sponsor_name":"Camilla Balle","has_results":false},{"nct_id":"NCT04392505","title":"Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT07008742","title":"Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false},{"nct_id":"NCT05657873","title":"A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":68,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT05274451","title":"A Study to Investigate LYL797 in Adults With Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":57,"lead_sponsor_name":"Lyell Immunopharma, Inc.","has_results":false},{"nct_id":"NCT07405190","title":"Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":46,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT02905591","title":"A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":43,"lead_sponsor_name":"Joseph J. Cullen, MD, FACS","has_results":false},{"nct_id":"NCT07408635","title":"IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":43,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false},{"nct_id":"NCT05429320","title":"A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT06667154","title":"Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":33,"lead_sponsor_name":"Aline Fusco Fares, MD","has_results":false},{"nct_id":"NCT07001995","title":"Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Hunan Province Tumor Hospital","has_results":false},{"nct_id":"NCT01999985","title":"Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT03689855","title":"Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT03215810","title":"Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":true},{"nct_id":"NCT04069936","title":"Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":19,"lead_sponsor_name":"WindMIL Therapeutics","has_results":false},{"nct_id":"NCT05631574","title":"Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":13,"lead_sponsor_name":"Biomea Fusion Inc.","has_results":false},{"nct_id":"NCT04849273","title":"A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Turning Point Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05891197","title":"A Biomarker Screening Protocol for Participants With Solid Tumors","phase":"","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Lyell Immunopharma, Inc.","has_results":false},{"nct_id":"NCT06889467","title":"Liquid Biopsy Assay of EBUS-TBNA Supernatant Fluid for Diagnosing Lung Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Barzilai Medical Center","has_results":false},{"nct_id":"NCT03131206","title":"A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":true},{"nct_id":"NCT06872489","title":"Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Second Life Therapeutics","has_results":false},{"nct_id":"NCT06797362","title":"Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Nuvalent Inc.","has_results":false},{"nct_id":"NCT06834074","title":"Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Nuvalent Inc.","has_results":false}],"total":30},"guidelines":[],"source":"Drug Landscape verified database"}